Home › Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer
 

Keywords :   


Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer

2015-01-13 14:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. & INDIANAPOLIS Combinations of KEYTRUDA (pembrolizumab) with Alimta (pemetrexed), Cyramza (ramucirumab), or necitumumab to be explored KENILWORTH, N.J. & INDIANAPOLIS--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Justin Holko, 908-740-1879orLillyEli Lilly and CompanyKeri McGrath, 317-277-3768Communications Managermcgrath_happeks@lilly.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: LLY Exchange: NYSE read more

Tags: enter research agreement types

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Tropical Storm Milton Public Advisory Number 2
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 26
05.10Tropical Storm Milton Graphics
05.10Hurricane Kirk Wind Speed Probabilities Number 26
05.10Hurricane Leslie Graphics
05.10Hurricane Kirk Public Advisory Number 26
05.10Summary for Hurricane Kirk (AT2/AL122024)
More »